Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12945 | 1.00 | CHRM5 (0.58) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL30340999 | 1.00 | CHRM5 (0.58) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL10949210 | 0.97 | CHRM5 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL11850078 | 0.92 | CYP1A2 (0.48) | CHRM5ADRA2CCYP1A2SIGMAR1CHRM3 | |
| SCHEMBL10153844 | 0.92 | CYP1A2 (0.54) | CHRM5ADRA2CCYP1A2HRH3 | |
| SCHEMBL8587237 | 0.90 | CYP1A2 (0.50) | CHRM5ADRA2CCYP1A2HRH3 | |
| SCHEMBL24146230 | 0.86 | CYP1A2 (0.44) | CHRM5ADRA2CCYP1A2SIGMAR1CHRM3 | |
| SCHEMBL30115021 | 0.86 | HRH3 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL30115019 | 0.86 | HRH3 (0.54) | CHRM5ADRA2CCYP1A2HRH3SIGMAR1 | |
| SCHEMBL7166922 | 0.85 | CYP1A2 (0.44) | CHRM5ADRA2CCYP1A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061779-B1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | CHRM5 4719/4885ADRA2C 3659/4885CYP1A2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.